102 results
Page 2 of 6
8-K
EX-99.3
6blqpat3
23 May 23
Regulation FD Disclosure
7:06am
8-K
EX-99.1
evd xbe2w59
23 May 23
Regulation FD Disclosure
7:06am
8-K
EX-99.1
8xq htdni0symt
15 May 23
OTL-200 Biologics License Application (BLA) submission completion anticipated in mid-2023
7:05am
8-K
EX-99.2
d7rkig
12 Dec 22
Regulation FD Disclosure
4:22pm
8-K
EX-99.1
avubu6v
14 Nov 22
Orchard Therapeutics Reports Third Quarter 2022 Financial Results and Reviews Recent Business Highlights
7:10am
8-K
EX-99.1
19244a4gb3ysrnu0
4 Aug 22
Orchard Therapeutics Reports Second Quarter 2022 Financial Results and Reviews Recent Business Highlights
7:05am
8-K
EX-99.1
jjr0r 0ve4
12 May 22
Orchard Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Commercial Progress
7:05am
8-K
EX-99.1
azc4shso
30 Mar 22
Results of Operations and Financial Condition
7:40am
8-K
EX-99.1
j3e919dbyy8
4 Feb 22
Orchard Therapeutics Announces Historic Agreement Making Libmeldy® Available by NHS England for MLD Patients
7:00am
8-K
EX-99.1
ogvbme6k
21 Jan 22
Other Events
7:05am
8-K
EX-99.1
4jtzyxt2x4j 6aef
10 Jan 22
Orchard Therapeutics Announces Recent Commercial and Regulatory Progress for Late-stage HSC Gene Therapy Programs and Outlines Key 2022 Milestones
7:05am
8-K
EX-99.1
ho3gjtpjpy55quazwi
18 Nov 21
Orchard Therapeutics Announces New England Journal of Medicine Publication of Interim Proof-of-concept Study Results of OTL-203 for Hurler Syndrome
7:05am
8-K
EX-99.1
xjc3989xnxxsq4f 1x
4 Nov 21
Orchard Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Business Updates
7:50am